AbbVie Inc (ABBV)vsRani Therapeutics Holdings Inc (RANI)
ABBV
AbbVie Inc
$227.23
-2.70%
HEALTHCARE · Cap: $380.57B
RANI
Rani Therapeutics Holdings Inc
$0.88
+2.03%
HEALTHCARE · Cap: $107.58M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 1982197% more annual revenue ($62.82B vs $3.17M). ABBV leads profitability with a 5.8% profit margin vs 0.0%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
RANI
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-55.6%
Fair Value
$146.00
Current Price
$227.23
$81.23 premium
Margin of Safety
+77.3%
Fair Value
$5.50
Current Price
$0.88
$4.62 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Revenue surging 893.0% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bull Case : RANI
The strongest argument for RANI centers on Revenue Growth, Debt/Equity. Revenue growth of 893.0% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 105.1x leaves little room for execution misses.
Bear Case : RANI
The primary concerns for RANI are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
ABBV profiles as a value stock while RANI is a hypergrowth play — different risk/reward profiles.
RANI carries more volatility with a beta of 0.76 — expect wider price swings.
RANI is growing revenue faster at 893.0% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 28/100) and 12.4% revenue growth. RANI offers better value entry with a 77.3% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Rani Therapeutics Holdings Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Rani Therapeutics Holdings Inc. is at the forefront of biotechnology innovation, transforming injectable therapies with its proprietary RaniPill™ technology that allows for oral delivery of biologics. This cutting-edge platform addresses significant patient adherence challenges, aiming to enhance treatment efficacy while meeting the rising demand for non-invasive therapeutic options. With a robust and diverse pipeline targeting multiple therapeutic areas, Rani Therapeutics is strategically positioned to disrupt traditional drug delivery paradigms. The company's commitment to research and development, coupled with strategic collaborations, underpins its potential for significant growth and impactful contributions to the pharmaceutical landscape.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?